Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Fuereder

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Current Opinion in Oncology|March 10, 2022
Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patientsThorsten Fuereder
Memo|July 19, 2016
Immunotherapy for head and neck squamous cell carcinomaThorsten Fuereder
Current Opinion in Oncology|October 1, 2024
Thymic malignancies: role of immunotherapy and novel approachesBarbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder
Frontiers in Oncology|March 19, 2025
Systemic therapy for laryngeal carcinomaThorsten Fuereder, Florian Kocher, Jan Baptist Vermorken
Oncology Research|January 8, 2024
New perspectives on biology, disease progression, and therapy response of head and neck cancer gained from single cell RNA sequencing and spatial transcriptomicsGerwin Heller, Thorsten Fuereder, Alexander Michael Grandits, et al.
Annals of Medicine|May 10, 2022
Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapyChristoph Minichsdorfer, Andreas Gleiss, Marie-Bernadette Aretin, et al.
Frontiers in Oncology|December 19, 2019
PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma PatientsChristoph Minichsdorfer, Felicitas Oberndorfer, Christoph Krall, et al.
European Journal of Clinical Pharmacology|July 27, 2022
Perception of clinical research among patients and healthy volunteers of clinical trialsFelix Bergmann, Peter Matzneller, Maria Weber, et al.
European Journal of Clinical Investigation|August 23, 2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpressionThorsten Fuereder, Judith Stift, Irene Kuehrer, et al.
The Journal of Investigative Dermatology|November 5, 2010
Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivoJohannes Werzowa, Stefan Koehrer, Sabine Strommer, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Current Opinion in Oncology|March 10, 2022
Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patientsThorsten Fuereder
Memo|July 19, 2016
Immunotherapy for head and neck squamous cell carcinomaThorsten Fuereder
Current Opinion in Oncology|October 1, 2024
Thymic malignancies: role of immunotherapy and novel approachesBarbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder
Frontiers in Oncology|March 19, 2025
Systemic therapy for laryngeal carcinomaThorsten Fuereder, Florian Kocher, Jan Baptist Vermorken
Oncology Research|January 8, 2024
New perspectives on biology, disease progression, and therapy response of head and neck cancer gained from single cell RNA sequencing and spatial transcriptomicsGerwin Heller, Thorsten Fuereder, Alexander Michael Grandits, et al.
Annals of Medicine|May 10, 2022
Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapyChristoph Minichsdorfer, Andreas Gleiss, Marie-Bernadette Aretin, et al.
Frontiers in Oncology|December 19, 2019
PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma PatientsChristoph Minichsdorfer, Felicitas Oberndorfer, Christoph Krall, et al.
European Journal of Clinical Pharmacology|July 27, 2022
Perception of clinical research among patients and healthy volunteers of clinical trialsFelix Bergmann, Peter Matzneller, Maria Weber, et al.
European Journal of Clinical Investigation|August 23, 2014
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpressionThorsten Fuereder, Judith Stift, Irene Kuehrer, et al.
The Journal of Investigative Dermatology|November 5, 2010
Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivoJohannes Werzowa, Stefan Koehrer, Sabine Strommer, et al.
Pageof 8